2023 World Conference on Lung Cancer (Posters)-EP14.04. BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

EP14.04. BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma - PDF(Slides)

Back to course

Pdf Summary

A study conducted by the Mayo Foundation for Medical Education and Research found that the presence or absence of the BRCA-Associated Protein-1 (BAP1) did not appear to affect the overall survival of patients receiving immunotherapy for pleural mesothelioma. The study analyzed real-world outcomes of 87 patients with pleural mesothelioma who had received immunotherapy between January 2014 and January 2023. Of the patients, 64 had epithelioid histology and 35 had BAP1 loss. Immunotherapy was administered as first-line treatment in 43 patients. The median overall survival was 12.0 months, and there was no statistical difference in survival between patients with epithelioid and non-epithelioid histology, BAP1 status, or the number of prior lines of therapy received. However, the study noted that the data may be confounded as only a few patients with BAP1 loss had non-epithelioid histology. Further research is needed to determine predictive markers for response to immunotherapy in mesothelioma and the clinical implications of BAP1 mutational status. The study contributes to the understanding of the effectiveness of immunotherapy in treating pleural mesothelioma, a rare malignancy with limited therapeutic options.

Asset Subtitle

Caleb Smith

Meta Tag

Speaker Caleb Smith

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

Mayo Foundation for Medical Education and Research

BRCA-Associated Protein-1

BAP1

pleural mesothelioma

immunotherapy

real-world outcomes

epithelioid histology

BAP1 loss

overall survival

predictive markers